Table 1.
Patient, tumor, and treatment characteristics by group of surgery
| Breast conserving surgery (n = 283) | Mastectomy (n = 153) | |||||
|---|---|---|---|---|---|---|
| CBCS (n = 95) | OBCS (n = 188) |
p value |
CM (n = 52) |
NSM/SSM (n = 101) |
Ρ value |
|
| Median patient age (Q1–Q3), years | 62.0 (51.0–72.0) | 61.0 (50.0–70.0) | 0.633 | 69.0 (59.5–80) | 51.0 (44.0–61.0) | <0.001 |
| T stage, n (%)a | ||||||
| pTis | 11 (11.6) | 24 (12.8) | 0.419 | 6 (11.5) | 20 (19.8) | 0.003 |
| pT0 | 6 (6.3) | 8 (4.3) | 1 (1.9) | 6 (5.9) | ||
| 60 (63.2) | 109 (58.0) | 11 (21.2) | 41 (40.6) | |||
| pT2 | 18 (18.9) | 40 (21.3) | 24 (46.2) | 26 (25.7) | ||
| pT3 | 0 (0.0) | 6 (3.2) | 7 (13.5) | 8 (7.9) | ||
| pT4 | 0 (0.0) | 0 (0.0) | 3 (5.8) | 0 (0.0) | ||
| N stage, n (%)a | ||||||
| pNX | 11 (11.6) | 12 (6.4) | 0.056 | 8 (15.4) | 4 (4.0) | 0.008 |
| pN0 | 64 (67.4) | 138 (73.4) | 19 (36.5) | 64 (63.4) | ||
| pN1 | 17 (17.9) | 27 (14.4) | 15 (28.8) | 22 (21.8) | ||
| pN2 | 3 (3.2) | 2 (1.1) | 5 (9.6) | 7 (6.9) | ||
| pN3 | 0 (0.0) | 8 (4.3) | 5 (9.6) | 4 (4.0) | ||
|
| ||||||
| Tumor grade, n (%)b | ||||||
| I | 24 (25.3) | 46 (24.5) | 0.460 | 5 (9.6) | 20 (19.8) | 0.184 |
| II | 44 (46.3) | 81 (43.1) | 26 (50.0) | 38 (37.6) | ||
| III | 21 (22.1) | 57 (30.3) | 20 (38.5) | 39 (38.6) | ||
| Cancer biology, n (%)c | ||||||
| Pure DCIS | 11 (11.6) | 23 (12.2) | 0.920 | 5 (9.6) | 19 (18.8) | 0.180 |
| Luminal A-like | 50 (52.6) | 91 (48.4) | 19 (36.5) | 37 (36.6) | ||
| Luminal B-like (Her2-negative) | 21 (22.1) | 40 (21.3) | 17 (32.7) | 23 (22.8) | ||
| Luminal B-like (Her2-positive) | 6 (6.3) | 15 (8.0) | 5 (9.6) | 7 (6.9) | ||
| Her2-positive (nonluminal) | 2 (2.1) | 9 (4.8) | 3 (5.8) | 2 (2.0) | ||
| Basal like | 4 (4.2) | 9 (4.8) | 2 (3.8) | 12 (11.9) | ||
| Margin after initial surgery, n (%) | ||||||
| Negative | 85 (89.5) | 162 (86.2) | 0.571 | 50 (96.2) | 94 (93.1) | 0.719 |
| Positive | 10 (10.5) | 26 (13.8) | 2 (3.8) | 7 (6.9) | ||
|
| ||||||
| Lymph node surgery, n (%)a | ||||||
| None | 14 (14.7) | 17 (9.0) | 0.521 | 9 (17.3) | 5 (5.0) | 0.001 |
| Sentinel lymph node biopsy | 68 (71.6) | 142 (75.5) | 19 (36.5) | 68 (67.3) | ||
| Tailored axillary surgeryd | 6 (6.3) | 11 (5.9) | 3 (5.8) | 6 (5.9) | ||
| Axillary lymph node dissection | 7 (7.4) | 17 (9.0) | 21 (40.4) | 22 (21.8) | ||
| Chemotherapy, n (%) | ||||||
| No chemotherapy | 76 (80.0) | 140 (74.5) | 0.590 | 35 (67.3) | 64 (63.4) | 0.388 |
| Adjuvant chemotherapy | 10 (10.5) | 31 (16.5) | 14 (26.9) | 22 (21.8) | ||
| Neoadjuvant chemotherapy | 8 (8.4) | 15 (8.0) | 3 (5.8) | 14 (13.9) | ||
| Both | 1 (1.1) | 2 (1.1) | 0 (0.0) | 1 (1.0) | ||
| Adjuvant radiotherapy, n (%) | 74 (77.9) | 161 (85.6) | 0.130 | 19 (36.5) | 34 (33.7) | 0.724 |
| Median time of follow-up (Q1–Q3), months | 34.46 (9.10–55.69) | 21.13 (6.37–35.42) | 0.004 | 18.15 (11.22–47.08) | 22.93 (8.71–40.48) | 0.731 |
DCIS, ductal carcinoma in situ. Missing:
a
1,
b
15,
c
4.
d
Tailored axillary surgery as surgical intervention in the TAXIS trial [30].